Navigation Links
Mirati Presents Clinical Response Results of Mocetinostat in Combination with Azacitidine as a Treatment for MDS
Date:12/9/2013

SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today presented data at the 2013 American Society of Hematology (ASH) Annual Meeting demonstrating promising clinical response rates in patients with myelodysplastic syndromes (MDS) patients treated with mocetinostat in combination with azacitidine.  Separately, Mirati announced that it has dosed the first patients in its Phase 2 dose confirmation trial of mocetinostat in combination with azacitidine for the treatment of MDS.

In an analysis of an open-label, Phase 1/2 trial of 66 patients with MDS or acute myeloid leukemia (AML), researchers analyzed a subset of 22 patients with Intermediate and High Risk disease and baseline bone marrow blasts of 5 to 20 percent at screening, representing a population of patients with RAEB-1 or RAEB-2, a type of MDS that is associated with poor clinical outcomes. Of the 22 patients treated with mocetinostat plus azacitidine, 59 percent experienced an objective response. Median overall survival was 12.4 months.

"Patients diagnosed with MDS have few treatment options, and, despite the advances with the standard of care treatment of azacitidine alone, there remains an unmet medical need to improve patient outcome," said Dr. Guillermo Garcia-Manero, professor in the department of leukemia, division of cancer medicine and deputy chair of translational research, department of leukemia, division of cancer medicine (co-chair) at MD Anderson Cancer Center and the principal investigator of the study. "Building upon the experience with azacitidine, our data show that the addition of mocetinostat to azacitidine results in an encouraging objective response rate, and a randomized registration trial is the next logical step."

In the open-label dose confirmation trial that began dosing p
'/>"/>

SOURCE Mirati Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Mirati Therapeutics Prices Public Offering Of Common Stock
2. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
3. Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
4. Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
5. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
6. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
7. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
8. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
9. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
10. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
11. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... -- The report, "Bottled Water Processing ... Blow molder, Shrink wrapper), Technology (RO, UF, MF, ... Region - Trends & Forecasts to 2019", published ... processing market with analyses and projection of the ... also identifies the driving and restraining factors for ...
(Date:2/26/2015)... , Feb. 26, 2015 People ... have the opportunity to participate in research that ... the first independent U.S. psoriasis registry begins recruiting ... joint collaboration with the National Psoriasis Foundation and ... reporting for secukinumab, a new biologic medication by ...
(Date:2/26/2015)... DIEGO , Feb. 26, 2015  MEI Pharma, Inc. ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at the Cowen and Company 35 ... 2015 at 10:40 a.m. Eastern time from the Boston Marriott ... accessed at www.meipharma.com . A replay will be available ...
Breaking Medicine Technology:Bottled Water Processing Market Worth $2,106.5 Million by 2019 2Bottled Water Processing Market Worth $2,106.5 Million by 2019 3Bottled Water Processing Market Worth $2,106.5 Million by 2019 4First independent U.S. psoriasis registry will track drug safety and effectiveness 2First independent U.S. psoriasis registry will track drug safety and effectiveness 3MEI Pharma to Present at Cowen and Company Health Care Conference 2MEI Pharma to Present at Cowen and Company Health Care Conference 3
... IRVINE, Calif., Nov. 16, 2010 Uptake Medical ... interventional emphysema therapy , announced today that J.C. ... and chief financial officer. MacRae comes to ... medical specialty device and biopharmaceutical product industries. He most ...
... Inc. (NYSE: PFE ) today announced ... Innovation, an entrepreneurial network of partnerships with leading ... by accessing leading translational researchers.  The University of ... the network. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ...
Cached Medicine Technology:Uptake Medical Names J.C. MacRae as Chief Financial Officer 2Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 2Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 3Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco 4
(Date:2/26/2015)... IL (PRWEB) February 26, 2015 Thousands ... small step to fund powerful progress for the Muscular ... by raising critical funds and awareness that will help ... fighting muscle disease. , “MDA Muscle Walk events unite ... for people whose abilities to move are compromised — ...
(Date:2/26/2015)... SpendWell Health, an online marketplace for ... first customer today, opening its doors to Cambia ... , SpendWell delivers the next generation of online ... transparency with e-commerce. SpendWell’s unique platform shows actual ... services and allows shoppers to buy those services ...
(Date:2/26/2015)... a nested-case control study of individuals living in the UK, ... of liver cancer, statin use is associated with a decreased ... published February 26 in the JNCI: Journal of the ... association but most used data from individuals living in regions ... Katherine A. McGlynn, Ph.D., from the Division of Cancer Epidemiology ...
(Date:2/26/2015)... NJ (PRWEB) February 26, 2015 The ... reopening of their newly renovated office in Lawrenceville, NJ. ... Reproductive Science Center of New Jersey’s physicians, and NJ ... and patient care in the areas of infertility and ... for having excellent success rates and providing current, high ...
(Date:2/26/2015)... The hip resurfacing procedure at ... Texas resident John Short to resume his active lifestyle, it ... to climb Mt. Kilimanjaro, the highest free-standing mountain in the ... Starting in his late 20s, Short suffered from early onset ... and sockets were bone on bone. , Then about ...
Breaking Medicine News(10 mins):Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 2Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 3Health News:SpendWell Launches New Online Health Care Marketplace to Large Employer Group 2Health News:SpendWell Launches New Online Health Care Marketplace to Large Employer Group 3Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 3Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 2Health News:Hip Resurfacing at Texas Orthopedics Enables Patient to Climb Mt. Kilimanjaro 3
... that break down pollutants do their job and then ... wastes. Research was conducted on those bacteria by cornell ... ethenogenes, discovered in Ithaca sewage sludge in 1997 by ... and isolated and studied by Stephen Zinder, Cornell professor ...
... wine halved in France since the 1950s, the world's number ... its saviour. But while the Chinese and Indians have ... worlds largest, there are those attending the two-yearly event who ... margins in China are not there. It is not ready ...
... New England Journal of Medicine,treating hepatitis B patients with the ... with HIV to become resistant to two of the most ... researchers reported that a patient infected with both hepatitis B ... strain of HIV that is resistant to the antiviral drugs ...
... first human trial of a locally-made H5N1 bird flu vaccine as ... officials in the communist country. The drug trial, to be ... of several global efforts to develop a vaccine for mass production, ... Asia. ,The news comes as a new wave of ...
... Boffins at the Scripps Research Institute have found in ... pleiotrophin (PTN) plays in accelerating breast cancer . ... in breast cancer had not been clearly established, and ... to a better understanding of the molecular pathogenesis of ...
... prostitute might have led Hitler to orchestrate the genocidal ... ,Hitler might have contracted syphilis, which, possibly untreated, ... Jews and the mentally retarded. ,There is ... Dr Bassem Habeeb. ,Dr Habeeb said that ...
Cached Medicine News:Health News:Insilico Studies on Chlorine Eating Bacteria 2Health News:Go for Russia, Not China, Wine Experts Say 2Health News:Go for Russia, Not China, Wine Experts Say 3Health News:Challenges in Entecavir Drug Treatment 2Health News:Vietnam Plans Human Trial of Bird Flu Vaccine 2Health News:Researchers Have Found the Role of Protein in Accelerating Breast Cancer Progression 2Health News:Researchers Have Found the Role of Protein in Accelerating Breast Cancer Progression 3Health News:Hitler's Holocaust may Have Stemmed from Syphilis from Jewish Prostitute 2
Inquire...
... intensity ,Smaller slot surface area results ... ,Small slot dimensions require less sample ... ,More intense signal generated with the slot-blotter allows ... Accepts all types of transfer membranes ...
... The Minifold I system consists of four basic ... plenum, and metal clamping plate (see diagram). The ... for producing spots, dots, or slots (see below). ... purchased as an accessory plate in conjunction with ...
... The Minifold I system consists of four ... vacuum plenum, and metal clamping plate (see diagram). ... configurations for producing spots, dots, or slots (see ... be purchased as an accessory plate in conjunction ...
Medicine Products: